用relugolix治疗的绝经前妇女的性功能,并为子宫纤维瘤添加回疗法:一项观察性研究
Matteo Mancarella1,2, Lorenzo Novara1, Silvia Carignano1,2
1Obstetrics and Gynecology University Department, Mauriziano Umberto I Hospital, Torino, Italy.
概括
瑞卢戈力克斯与补充治疗相结合,有效地减少了子宫纤维瘤的大小和出血症状. 然而,这种治疗在半年内对绝经前妇女的性功能没有显著影响.
科学领域:
- 生殖内分泌学 生殖内分泌学
- 妇科 妇科 妇科 妇科
- 药理学 药理学 是一个学科.
背景情况:
- 子宫肌瘤 (纤维瘤) 导致大量出血和大量症状,影响生活质量.
- 雷卢戈利克斯是一种GnRH抗剂,附加治疗 (ABT),是症状性纤维瘤的新治疗选择.
- 由于纤维瘤收缩的潜在好处和低雌激素的风险,relugolix-ABT对性功能的影响尚不确定.
研究的目的:
- 评估relugolix-ABT对有症状的子宫瘤的绝经前妇女的性功能的影响.
- 为了评估治疗后女性性功能指数 (FSFI) 评分的变化.
主要方法:
- 一项涉及21名患有症状子宫纤维瘤的绝经前妇女的研究.
- 使用口服的relugolix (40毫克) 加上ABT (雌激醇1毫克+诺列乙酸0.5毫克) 的治疗.
- 在基线和6个月后使用FSFI问卷评估性功能.
主要成果:
- 在6个月后,FSFI总得分没有出现统计学上显著的变化 (23.0对23.1,p=0.70).
- 纤维瘤总体积 (p=0.019) 和平均直径 (p=0.011) 的显著减少.
- 在87.5%的病例中,有效控制出血.
结论:
- 瑞卢戈力克斯-ABT有效地减少子宫纤维瘤的大小,并控制出血,耐受性良好.
- 治疗没有导致性功能在统计学上显著的变化.
- 进一步的研究可能会探索性功能的长期影响和特定方面.
更多相关视频
05:32Author Spotlight: Investigating the Relationship Between FSH and Pathophysiological Changes in Perimenopausal Women - Insights from a Mouse Model
Published on: August 11, 2023
2.4K
03:30Author Spotlight: Advancing Pelvic Prolapse Treatment with a Non-Mesh Approach using Laparoscopic Pectopexy
Published on: October 25, 2024
2.4K
相关概念视频
Menopause
3.5K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
3.5K
Hormonal Regulation of the Menstrual Cycle
1.4K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
1.4K
Drugs for Treatment of Diarrhea-Predominant IBS
625
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
625
Hormonal Control of the Ovarian Cycle
6.4K
The ovarian cycle is meticulously regulated by the hypothalamic-pituitary-gonadal axis. This cycle orchestrates the release of a mature oocyte, essential for reproduction.
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
Before puberty, the hypothalamus releases GnRH in a low frequency, low amplitude pulsatile manner. This along with the immature hypothalamic-pituitary-gonadal axis activity, results in low estrogen levels and the absence of a fully functional ovarian cycle. At puberty, GnRH secretion increases in both frequency and...
6.4K
Infertility in Females
3.6K
Female infertility is defined as the inability to conceive after a year of regular, unprotected intercourse and affects about 10–15% of couples worldwide. The primary cause of female infertility is ovulatory disorders, which hinder the release of eggs. These disorders can be classified as hypothalamic amenorrhea, polycystic ovarian syndrome (PCOS), premature ovarian failure, and hyperprolactinemic anovulation disorders.
Endometriosis, a condition characterized by abnormal growth of...
Endometriosis, a condition characterized by abnormal growth of...
3.6K
